Nabiximols (trade name Sativex) is a cannabinoid mouth spray developed by the UK company GW Pharmaceuticals for multiple sclerosis (MS) patients, who can use it to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms. Nabiximols is also being developed in Phase III trials as a potential treatment to alleviate pain due to cancer. It has also been researched in various models of peripheral and central neuropathic pain.
Nabiximols is distinct from all other pharmaceutically produced cannabinoids currently available because it is derived from cannabis plants, rather than a solely synthetic process. The drug is a pharmaceutical product standardized in composition, formulation, and dose, although it is still effectively a tincture of the cannabis plant. Its principal active cannabinoid components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). The product is formulated as an oromucosal spray which is administered into the mouth. Each spray delivers a fixed dose of 2.7 mg THC and 2.5 mg CBD.